INBRIJA HAS A WELL-ESTABLISHED SAFETY PROFILE
INBRIJA was generally well tolerated by patients with Parkinson’s
The most frequent adverse reactions reported in the INBRIJA clinical studies were cough (15.6%), fall (8.7%), upper respiratory tract infection (5.8%), dyskinesia (5.7%) and sputum discoloured (2.8%).1
Adverse reactions with INBRIJA1
Very common (≥1/10) |
Cough |
Common
(≥1/100 to <1/10) |
Dyskinesia, Upper respiratory tract infection, Sputum discoloured, Nasal discharge discolouration, Throat irritation, Nausea, Vomiting, Fall |
Not known (cannot be estimated from the available data) |
Sensation of choking |
2% of 114 patients discontinued INBRIJA 84 mg due to cough2
White text darf nicht unausgefüllt sein
In a one-year safety extension study, patients taking INBRIJA demonstrated preserved lung function, reflecting long-term respiratory safety.3
References: 1. Inbrija Summary of Product Characteristics. Available at https://www.ema.europa.eu/en/documents/product-information/inbrija-epar-product-information_en.pdf. Last Accessed May 2025. 2. LeWitt PA, Hauser RA, Pahwa R, et al; SPAN-PD Study Investigators. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145-154. 3. Farbman ES, Waters CH, LeWitt PA, et al. A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2020;81:144-150.